Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors

Eli Lilly and Company (NYSE:LLY) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors.

On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027. The company plans to target the out-of-pocket telehealth market, following the same approach it has used in the United States.

At the same time, Lilly intends to continue pursuing public reimbursement from European governments where possible, even as new US drug pricing policies add complexity to discussions with health authorities. Patrik Jonsson, Lilly’s head of international operations, said Europe and the UK are likely to be among the next markets to receive the company’s weight-loss treatment after approvals in the US and the UAE. He noted that Lilly plans to launch the drug as soon as it receives regulatory approval and will use telehealth partnerships and direct-to-patient channels as part of its effort to expand its consumer-focused obesity business beyond the US.

Jonsson also said the company will continue seeking reimbursement through public healthcare systems where available. He acknowledged that the Trump administration’s most-favored-nation pricing policy is expected to play a role in pricing negotiations and future product launches. His comments come at a time when pharmaceutical companies and European governments remain divided over drug pricing and its potential impact on profitability in the US.

Eli Lilly and Company (NYSE:LLY) is a medicine company that discovers, develops, manufactures, and markets products through a single business segment focused on human pharmaceutical products.

READ NEXT: Top 10 Blue Chip Stocks with Growing Dividends and Billionaire Mario Gabelli’s Top 12 Dividend Stocks

Disclosure: None. Follow Insider Monkey on Google News.